Literature DB >> 18936454

Use of evidence-based therapies after discharge among elderly patients with acute myocardial infarction.

Peter C Austin1, Jack V Tu, Dennis T Ko, David A Alter.   

Abstract

BACKGROUND: Postdischarge use of evidence-based drug therapies has been proposed as a measure of quality of care for myocardial infarction patients. We examined trends in the use of evidence-based drug therapies after discharge among elderly patients with myocardial infarction.
METHODS: We performed a cross-sectional study in a retrospective population-based cohort that was created using linked administrative databases. We included patients aged 65 years and older who were discharged from hospital with a diagnosis of myocardial infarction between Apr. 1, 1992, and Mar. 31, 2005. We determined the annual percentage of patients who filled a prescription for statins, beta-blockers and angiotensin-modifying drugs within 90 days after discharge.
RESULTS: The percentage of patients who filled a prescription for a beta-blocker increased from 42.6% in 1992 to 78.1% in 2005. The percentage of patients who filled a prescription for an angiotensin-modifying drug increased from 42.0% in 1992 to 78.4% in 2005. The percentage of patients who filled a prescription for a statin increased from 4.2% in 1992 to 79.2% in 2005. In 2005, about half of the hospitals had rates of use for each of these therapies that were less than 80%. The temporal rate of increase in statin use after discharge was slower among noncardiologists than among cardiologists (3.5%-2.8% slower). The rate of increase was 4.8% slower for among physicians with low volumes of myocardial infarction patients than among those with high volumes of such patients and was 5.7% greater at teaching hospitals compared with nonteaching hospitals.
INTERPRETATION: Use of statins, beta-blockers and angiotensin-modifying drugs increased from 1992 to 2005. The rate of increase in the use of these medications after discharge varied across physician and hospital characteristics.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18936454      PMCID: PMC2565720          DOI: 10.1503/cmaj.071481

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  19 in total

1.  Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group.

Authors:  M D Flather; S Yusuf; L Køber; M Pfeffer; A Hall; G Murray; C Torp-Pedersen; S Ball; J Pogue; L Moyé; E Braunwald
Journal:  Lancet       Date:  2000-05-06       Impact factor: 79.321

2.  Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials.

Authors:  J C LaRosa; J He; S Vupputuri
Journal:  JAMA       Date:  1999 Dec 22-29       Impact factor: 56.272

3.  The use of angiotensin-converting enzyme inhibitors in patients with acute myocardial infarction in community hospitals. Michigan State University Inter-Institutional Collaborative Heart (MICH) Study Group.

Authors:  F C Dwamena; H El-Tamimi; R E Watson; J Kroll; A D Stein; A McLane; M Holmes-Rovner; B McIntosh; J Kupersmith
Journal:  Clin Cardiol       Date:  2000-05       Impact factor: 2.882

4.  Temporal changes in the outcomes of acute myocardial infarction in Ontario, 1992-1996.

Authors:  J V Tu; C D Naylor; P Austin
Journal:  CMAJ       Date:  1999-11-16       Impact factor: 8.262

5.  Trends in acute myocardial infarction in 4 US states between 1992 and 2001: clinical characteristics, quality of care, and outcomes.

Authors:  Frederick A Masoudi; JoAnne M Foody; Edward P Havranek; Yongfei Wang; Martha J Radford; Richard M Allman; Jay Gold; R Todd Wiblin; Harlan M Krumholz
Journal:  Circulation       Date:  2006-12-04       Impact factor: 29.690

6.  beta Blockade after myocardial infarction: systematic review and meta regression analysis.

Authors:  N Freemantle; J Cleland; P Young; J Mason; J Harrison
Journal:  BMJ       Date:  1999-06-26

7.  Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction.

Authors:  S B Soumerai; T J McLaughlin; D Spiegelman; E Hertzmark; G Thibault; L Goldman
Journal:  JAMA       Date:  1997-01-08       Impact factor: 56.272

8.  National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project.

Authors:  H M Krumholz; M J Radford; Y Wang; J Chen; A Heiat; T A Marciniak
Journal:  JAMA       Date:  1998-08-19       Impact factor: 56.272

9.  Cardiologists' practices compared with practice guidelines: use of beta-blockade after acute myocardial infarction.

Authors:  D A Brand; L N Newcomer; A Freiburger; H Tian
Journal:  J Am Coll Cardiol       Date:  1995-11-15       Impact factor: 24.094

10.  Use of angiotensin-converting enzyme inhibitors at discharge in patients with acute myocardial infarction in the United States: data from the National Registry of Myocardial Infarction 2.

Authors:  H V Barron; A D Michaels; C Maynard; N R Every
Journal:  J Am Coll Cardiol       Date:  1998-08       Impact factor: 24.094

View more
  16 in total

Review 1.  Myocardial infarction and quality of care.

Authors:  Jersey Chen; Sharon-Lise T Normand
Journal:  CMAJ       Date:  2008-10-21       Impact factor: 8.262

2.  Association of long-term adherence to evidence-based combination drug therapy after acute myocardial infarction with all-cause mortality. A prospective cohort study based on claims data.

Authors:  Jutta Kuepper-Nybelen; Martin Hellmich; Sascha Abbas; Peter Ihle; Reinhard Griebenow; Ingrid Schubert
Journal:  Eur J Clin Pharmacol       Date:  2012-04-04       Impact factor: 2.953

3.  Secular trends in acute coronary syndrome hospitalization from 1994 to 2005.

Authors:  Dennis T Ko; Alice M Newman; David A Alter; Peter C Austin; Maria Chiu; Jafna L Cox; Shaun G Goodman; Jack V Tu
Journal:  Can J Cardiol       Date:  2010-03       Impact factor: 5.223

4.  Pattern of use of β-blockers in older patients with stable coronary artery disease: an observational, cross-sectional, multicentre survey.

Authors:  Cristiana Vitale; Ilaria Spoletini; Maurizio Volterrani; Ferdinando Iellamo; Massimo Fini
Journal:  Drugs Aging       Date:  2011-09-01       Impact factor: 3.923

5.  Trends in prescribing rate of statins at discharge and modifiable factors in patients with atherosclerotic cardiovascular disease.

Authors:  Bao-Tao Huang; Yong Peng; Fang-Yang Huang; Tian-Li Xia; Yi-Yue Gui; Yan-Biao Liao; Xiao-Bo Pu; Shi-Jian Chen; Yong Yang; Mao Chen
Journal:  Intern Emerg Med       Date:  2017-06-08       Impact factor: 3.397

6.  Variation in initiating secondary prevention after myocardial infarction by hospitals and physicians, 1997 through 2004.

Authors:  Andrea V Margulis; Niteesh K Choudhry; Colin R Dormuth; Sebastian Schneeweiss
Journal:  Pharmacoepidemiol Drug Saf       Date:  2011-04-28       Impact factor: 2.890

Review 7.  Cardiovascular disease in end-stage renal disease: the challenge of assessing and managing cardiac disease in dialysis patients.

Authors:  Lisa M Miller; Manish M Sood; Amy R Sood; Martina Reslerova; Paul Komenda; Claudio Rigatto; Joe Bueti
Journal:  Int Urol Nephrol       Date:  2010-10-20       Impact factor: 2.370

8.  Factors associated with the use of evidence-based therapies after discharge among elderly patients with myocardial infarction.

Authors:  Peter C Austin; Jack V Tu; Dennis T Ko; David A Alter
Journal:  CMAJ       Date:  2008-10-21       Impact factor: 8.262

9.  Trends in 1-year survival of people admitted to hospital in Ontario, 1994-2009.

Authors:  Carl van Walraven
Journal:  CMAJ       Date:  2013-09-30       Impact factor: 8.262

10.  Association of Region and Hospital and Patient Characteristics With Use of High-Intensity Statins After Myocardial Infarction Among Medicare Beneficiaries.

Authors:  Vera Bittner; Lisandro D Colantonio; Yuling Dai; Mark Woodward; Matthew T Mefford; Robert S Rosenson; Paul Muntner; Keri L Monda; Meredith L Kilgore; Byron C Jaeger; Emily B Levitan
Journal:  JAMA Cardiol       Date:  2019-09-01       Impact factor: 14.676

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.